In conclusion, mpMRI and [68Ga]Ga-PSMA-11 PET-CT are complementary techniques to be used in conjunction for the primary T staging and N staging in patients with intermediate- and high-risk prostate cancer, which, in addition to knowledge of the stage of the disease, also provide data on the location of lesions, which is important for planning the optimal treatment for patients. This evidence concerns the gene FOLH1 and prostate cancer.